Mesenchymal stem cell-derived extracellular vesicles for kidney repair: Current status and looming challenges

Arash Aghajani Nargesi, Lilach O Lerman, Alfonso Eirin

Research output: Contribution to journalReview article

32 Citations (Scopus)

Abstract

Novel therapies are urgently needed to address the rising incidence and prevalence of acute kidney injury (AKI) and chronic kidney disease (CKD). Mesenchymal stem/stromal cells (MSCs) have shown promising results in experimental AKI and CKD, and have been used in the clinic for more than a decade with an excellent safety profile. The regenerative effects of MSCs do not rely on their differentiation and ability to replace damaged tissues, but are primarily mediated by the paracrine release of factors, including extracellular vesicles (EVs), composed of microvesicles and exosomes. MSC-derived EVs contain genetic and protein material that upon transferring to recipient cells can activate several repair mechanisms to ameliorate renal injury. Recent studies have shown that MSC-derived EV therapy improved renal outcomes in several animal models of AKI and CKD, including ischemia-reperfusion injury, drug/toxin-induced nephropathy, renovascular disease, ureteral obstruction, and subtotal nephrectomy. However, data about the renoprotective effects of EV therapy in patients with renal failure are scarce. This review summarizes current knowledge of MSC-derived EV therapy in experimental AKI and CKD, and discusses the challenges that need to be addressed in order to consider MSC-derived EVs as a realistic clinical tool to treat patients with these conditions.

Original languageEnglish (US)
Article number273
JournalStem Cell Research and Therapy
Volume8
Issue number1
DOIs
StatePublished - Dec 4 2017

Fingerprint

Stem cells
Mesenchymal Stromal Cells
Repair
Kidney
Chronic Renal Insufficiency
Acute Kidney Injury
Extracellular Vesicles
Animals
Tissue
Exosomes
Ureteral Obstruction
Investigational Therapies
Reperfusion Injury
Nephrectomy
Pharmaceutical Preparations
Renal Insufficiency
Proteins
Therapeutics
Animal Models
Safety

Keywords

  • Exosomes
  • Extracellular vesicles
  • Kidney
  • Mesenchymal stem cells
  • Microvesicles

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Molecular Medicine
  • Biochemistry, Genetics and Molecular Biology (miscellaneous)
  • Cell Biology

Cite this

Mesenchymal stem cell-derived extracellular vesicles for kidney repair : Current status and looming challenges. / Aghajani Nargesi, Arash; Lerman, Lilach O; Eirin, Alfonso.

In: Stem Cell Research and Therapy, Vol. 8, No. 1, 273, 04.12.2017.

Research output: Contribution to journalReview article

@article{7ca510737e7f44329e89c834d40bd0b4,
title = "Mesenchymal stem cell-derived extracellular vesicles for kidney repair: Current status and looming challenges",
abstract = "Novel therapies are urgently needed to address the rising incidence and prevalence of acute kidney injury (AKI) and chronic kidney disease (CKD). Mesenchymal stem/stromal cells (MSCs) have shown promising results in experimental AKI and CKD, and have been used in the clinic for more than a decade with an excellent safety profile. The regenerative effects of MSCs do not rely on their differentiation and ability to replace damaged tissues, but are primarily mediated by the paracrine release of factors, including extracellular vesicles (EVs), composed of microvesicles and exosomes. MSC-derived EVs contain genetic and protein material that upon transferring to recipient cells can activate several repair mechanisms to ameliorate renal injury. Recent studies have shown that MSC-derived EV therapy improved renal outcomes in several animal models of AKI and CKD, including ischemia-reperfusion injury, drug/toxin-induced nephropathy, renovascular disease, ureteral obstruction, and subtotal nephrectomy. However, data about the renoprotective effects of EV therapy in patients with renal failure are scarce. This review summarizes current knowledge of MSC-derived EV therapy in experimental AKI and CKD, and discusses the challenges that need to be addressed in order to consider MSC-derived EVs as a realistic clinical tool to treat patients with these conditions.",
keywords = "Exosomes, Extracellular vesicles, Kidney, Mesenchymal stem cells, Microvesicles",
author = "{Aghajani Nargesi}, Arash and Lerman, {Lilach O} and Alfonso Eirin",
year = "2017",
month = "12",
day = "4",
doi = "10.1186/s13287-017-0727-7",
language = "English (US)",
volume = "8",
journal = "Stem Cell Research and Therapy",
issn = "1757-6512",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Mesenchymal stem cell-derived extracellular vesicles for kidney repair

T2 - Current status and looming challenges

AU - Aghajani Nargesi, Arash

AU - Lerman, Lilach O

AU - Eirin, Alfonso

PY - 2017/12/4

Y1 - 2017/12/4

N2 - Novel therapies are urgently needed to address the rising incidence and prevalence of acute kidney injury (AKI) and chronic kidney disease (CKD). Mesenchymal stem/stromal cells (MSCs) have shown promising results in experimental AKI and CKD, and have been used in the clinic for more than a decade with an excellent safety profile. The regenerative effects of MSCs do not rely on their differentiation and ability to replace damaged tissues, but are primarily mediated by the paracrine release of factors, including extracellular vesicles (EVs), composed of microvesicles and exosomes. MSC-derived EVs contain genetic and protein material that upon transferring to recipient cells can activate several repair mechanisms to ameliorate renal injury. Recent studies have shown that MSC-derived EV therapy improved renal outcomes in several animal models of AKI and CKD, including ischemia-reperfusion injury, drug/toxin-induced nephropathy, renovascular disease, ureteral obstruction, and subtotal nephrectomy. However, data about the renoprotective effects of EV therapy in patients with renal failure are scarce. This review summarizes current knowledge of MSC-derived EV therapy in experimental AKI and CKD, and discusses the challenges that need to be addressed in order to consider MSC-derived EVs as a realistic clinical tool to treat patients with these conditions.

AB - Novel therapies are urgently needed to address the rising incidence and prevalence of acute kidney injury (AKI) and chronic kidney disease (CKD). Mesenchymal stem/stromal cells (MSCs) have shown promising results in experimental AKI and CKD, and have been used in the clinic for more than a decade with an excellent safety profile. The regenerative effects of MSCs do not rely on their differentiation and ability to replace damaged tissues, but are primarily mediated by the paracrine release of factors, including extracellular vesicles (EVs), composed of microvesicles and exosomes. MSC-derived EVs contain genetic and protein material that upon transferring to recipient cells can activate several repair mechanisms to ameliorate renal injury. Recent studies have shown that MSC-derived EV therapy improved renal outcomes in several animal models of AKI and CKD, including ischemia-reperfusion injury, drug/toxin-induced nephropathy, renovascular disease, ureteral obstruction, and subtotal nephrectomy. However, data about the renoprotective effects of EV therapy in patients with renal failure are scarce. This review summarizes current knowledge of MSC-derived EV therapy in experimental AKI and CKD, and discusses the challenges that need to be addressed in order to consider MSC-derived EVs as a realistic clinical tool to treat patients with these conditions.

KW - Exosomes

KW - Extracellular vesicles

KW - Kidney

KW - Mesenchymal stem cells

KW - Microvesicles

UR - http://www.scopus.com/inward/record.url?scp=85037076116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037076116&partnerID=8YFLogxK

U2 - 10.1186/s13287-017-0727-7

DO - 10.1186/s13287-017-0727-7

M3 - Review article

C2 - 29202871

AN - SCOPUS:85037076116

VL - 8

JO - Stem Cell Research and Therapy

JF - Stem Cell Research and Therapy

SN - 1757-6512

IS - 1

M1 - 273

ER -